News

News 28.10.2020 Zurich-Schlieren, Switzerland, October 28, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and Novartis (SIX: NOVN) today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize...

News 20.10.2020 Schlieren (Zurich), Switzerland, October 20, 2020 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of shares placed and gross proceeds raised in the capital increase first announced on October 5, 2020, in which a total of 10,341,432 newly registered shares of Kuros with a nominal value...

Events, External events
Event date: 14.10.2020 Wed, Oct 14, 2020 09:30 AM – 12:00 AM CET Please join our free October Webinar “from Bench to Production” in Cell and Gene Therapy! An open platform to learn how Thermo Fisher can support your efforts to gain efficiency in your workflows and to learn from other BioTech organizations. This...

Events, External events
Event date: 29.10.2020 Thu, Oct 29, 2020 8:00 AM - 9:00 AM CET As a start-up, chances are you are currently or in the foreseeable future raising money. You certainly want to make sure to present yourself and your company in the best light in front of the investors. To achieve this, it would...

News 06.10.2020 Zurich-Schlieren, Switzerland, October 6, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced supportive preclinical data from in vivo assessments of its DARPin® candidates targeting SARS-CoV-2. These candidates show robust activity in an...